2020
Treatment patterns and survival in hepatocellular carcinoma in the United States and Taiwan
Lin YJ, Lin CN, Sedghi T, Hsu SH, Gross CP, Wang JD, Wang SY. Treatment patterns and survival in hepatocellular carcinoma in the United States and Taiwan. PLOS ONE 2020, 15: e0240542. PMID: 33052942, PMCID: PMC7556438, DOI: 10.1371/journal.pone.0240542.Peer-Reviewed Original ResearchGeographic Variations of Potentially Curative Treatments for Hepatocellular Carcinoma in the United States: A SEER-Medicare Study.
Cheng E, Hung P, Wang SY. Geographic Variations of Potentially Curative Treatments for Hepatocellular Carcinoma in the United States: A SEER-Medicare Study. Journal Of The National Comprehensive Cancer Network 2020, 18: 729-736. PMID: 32502978, DOI: 10.6004/jnccn.2020.7529.Peer-Reviewed Original ResearchConceptsHospital referral regionsCurative treatmentHepatocellular carcinomaIncidence of HCCCox proportional hazards modelSEER-Medicare studyPercutaneous ethanol injectionHepatitis B virusProportional hazards modelMore comorbiditiesSurgical resectionSurvival benefitTreatment patternsSEER-MedicareB virusRadiofrequency ablationEthanol injectionTreatment utilizationReferral regionsBetter survivalLower riskHazards modelPatientsSurvivalTreatment
2016
Assessing cost-utility of predictive biomarkers in oncology: a streamlined approach
Safonov A, Wang S, Gross CP, Agarwal D, Bianchini G, Pusztai L, Hatzis C. Assessing cost-utility of predictive biomarkers in oncology: a streamlined approach. Breast Cancer Research And Treatment 2016, 155: 223-234. PMID: 26749360, PMCID: PMC5990969, DOI: 10.1007/s10549-016-3677-3.Peer-Reviewed Original ResearchConceptsQuality-adjusted life yearsCost-effectiveness analysisPredictive biomarkersBiomarker-guided treatmentIncremental cost-effectiveness ratioHealth-related qualityTreatment costsCost-effectiveness ratioClinical outcomesClinical efficacyPrognostic biomarkerTraditional cost-effectiveness analysisBiomarker useLife yearsBiomarker valuesBiomarker prevalenceClinical literatureBiomarkersTreatmentState transition modelDecision analytic approachMedical utilityDecision analytic toolsCrizotinibHER2
2010
Incorporating margin status information in treatment decisions for women with ductal carcinoma in situ: a decision analysis
Wang SY, Kuntz K, Tuttle T, Kane R. Incorporating margin status information in treatment decisions for women with ductal carcinoma in situ: a decision analysis. Breast Cancer Research And Treatment 2010, 124: 393-402. PMID: 20848183, DOI: 10.1007/s10549-010-1166-7.Peer-Reviewed Original ResearchMeSH KeywordsBreast NeoplasmsCarcinoma, Intraductal, NoninfiltratingDecision Support TechniquesFemaleHumansMarkov ChainsMastectomy, SegmentalMiddle AgedNeoplasm Recurrence, LocalPatient PreferencePatient SelectionQuality-Adjusted Life YearsRadiotherapy, AdjuvantRisk AssessmentRisk FactorsTime FactorsTreatment OutcomeConceptsBreast-conserving surgeryQuality-adjusted life yearsRadiation therapyMargin statusDuctal carcinomaRT side effectsDecision-analytic Markov modelOne-way sensitivity analysesImportance of patientsProbabilistic sensitivity analysesDCIS treatmentInvasive recurrenceSalvage mastectomyOptimal treatmentHypothetical cohortTreatment decisionsLifetime horizonSide effectsLife yearsDCISPatientsWomenCarcinomaTreatment